Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 3/20 | 0.59 |
| ▸ | MMP13 | P45452 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6342203 | 0.82 | HTT (0.54) | MMP12MMP13HTTGAACYP1A2 | |
| SCHEMBL25490128 | 0.82 | HTT (0.58) | MMP12MMP13HTTGAACYP1A2 | |
| SCHEMBL15896281 | 0.80 | MMP12 (0.60) | MMP12MMP13HTTGAACYP1A2 | |
| SCHEMBL25490135 | 0.79 | ALDH1A1 (0.54) | MMP12MMP13HTTGAACYP1A2 | |
| SCHEMBL28747284 | 0.79 | MMP12 (0.66) | MMP12MMP13HTTGAACYP1A2 | |
| SCHEMBL6342584 | 0.79 | MMP12 (0.66) | MMP12MMP13HTTGAACYP1A2 | |
| SCHEMBL6412998 | 0.78 | MMP12 (0.56) | MMP12MMP13HTTGAACYP1A2 | |
| SCHEMBL6413015 | 0.78 | MMP12 (0.56) | MMP12MMP13HTTGAACYP1A2 | |
| SCHEMBL7987526 | 0.78 | KEAP1 (0.55) | MMP12MMP13HTTGAACYP1A2 | |
| SCHEMBL6843967 | 0.78 | MMP12 (0.58) | MMP12MMP13HTTGAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624177-B1 | Treating diseases in which matrix melatoproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | claimed |
| EP-0931045-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1999-07-28 | — | — | EP | claimed |
| WO-1998009934-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | claimed |
| US-6906092-B2 | Method of inhibiting matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
| US-20040029945-A1 | Method of inhibiting matrix metalloproteinases | O'BRIEN PATRICK MICHAEL (US) | 2004-02-12 | — | — | US | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| US-6624177-B1 | Treating diseases in which matrix melatoproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-6620835-B2 | Sulfonamide-substituted benzothiophenes (that may be oxidized), carbazoles, fluorenes and fluorenones | WARNER-LAMBERT COMPANY | 2003-09-16 | — | — | US | disclosed |
| US-20030032665-A1 | Method of inhibiting matrix metalloproteinases | O'BRIEN PATRICK MICHAEL (US) | 2003-02-13 | — | — | US | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| EP-0946166-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| US-5948780-A | ADMINISTERING A METALLOPROTEINASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| EP-0931045-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999032150-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998025597-A2 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
| WO-1998009934-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP12 21/4885MMP13 13/4885HTT 1885/4885 |
| US-20030032665-A1 | Method of inhibiting matrix metalloproteinases | MMP17, MMP1, MMP12 | MMP12 3/4885MMP13 11/4885HTT 4767/4885 |
| US-20040029945-A1 | Method of inhibiting matrix metalloproteinases | MMP17, MMP1, MMP12 | MMP12 3/4885MMP13 11/4885HTT 4767/4885 |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP12 21/4885MMP13 13/4885HTT 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.